CA2200468A1 - Antagonistes de muscarine - Google Patents

Antagonistes de muscarine

Info

Publication number
CA2200468A1
CA2200468A1 CA002200468A CA2200468A CA2200468A1 CA 2200468 A1 CA2200468 A1 CA 2200468A1 CA 002200468 A CA002200468 A CA 002200468A CA 2200468 A CA2200468 A CA 2200468A CA 2200468 A1 CA2200468 A1 CA 2200468A1
Authority
CA
Canada
Prior art keywords
piperidin
dihydro
benzimidazol
pyrimidinecarbonyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002200468A
Other languages
English (en)
Inventor
Wayne J. Thompson
Michael F. Sugrue
Richard W. Ransom
Pierre J. Mallorga
Ian M. Bell
Anthony M. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/329,757 external-priority patent/US5574044A/en
Priority claimed from US08/440,153 external-priority patent/US5691323A/en
Application filed by Individual filed Critical Individual
Publication of CA2200468A1 publication Critical patent/CA2200468A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composés, 1,3-dihydro-1-{1-[pipéridine-4-yl]pipéridine-4-yl}-2H-benzimidazole-2-ones et 1,3 dihydro-1-{4-amino-1-cyclohexyl}-2H-benzimidazole-2-ones et dérivés desdites substances, leur préparation, procédé d'utilisation et compositions pharmaceutiques. Lesdits composés possèdent une activité antimuscarinique et sont utiles dans le traitement et/ou la prévention de la myopie.
CA002200468A 1994-10-27 1995-10-24 Antagonistes de muscarine Abandoned CA2200468A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/329,757 US5574044A (en) 1994-10-27 1994-10-27 Muscarine antagonists
US329,757 1994-10-27
US08/440,153 US5691323A (en) 1995-05-12 1995-05-12 Muscarine antagonists
US440,153 1995-05-12

Publications (1)

Publication Number Publication Date
CA2200468A1 true CA2200468A1 (fr) 1996-05-09

Family

ID=26986957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002200468A Abandoned CA2200468A1 (fr) 1994-10-27 1995-10-24 Antagonistes de muscarine

Country Status (5)

Country Link
EP (1) EP0786997A4 (fr)
JP (1) JP2002515008A (fr)
AU (1) AU701127B2 (fr)
CA (1) CA2200468A1 (fr)
WO (1) WO1996013262A1 (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751647B1 (fr) * 1996-07-25 1998-09-11 Synthelabo Derives de benzimidazole, leurs preparations et leurs applications en therapeutique
DE19643331A1 (de) * 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE69826278T2 (de) 1997-05-30 2005-11-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazol-derivate
WO1999032479A1 (fr) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Derives de phtalamidepiperidine, de phtalamidepyrrolidine, et de phtalamide-azepine, leur preparation, et leur utilisation comme agonistes(antagonistes) des recepteurs muscariniques
US7501425B1 (en) 1998-05-26 2009-03-10 Warner Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
WO2001027104A1 (fr) 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Derives d'imidazolidinone a substitution
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
CN100352816C (zh) * 2001-04-18 2007-12-05 欧罗赛铁克股份有限公司 伤害感受肽类似物
EP1386920A4 (fr) * 2001-04-20 2005-09-14 Banyu Pharma Co Ltd Derives de benzimidazolone
CA2457647A1 (fr) 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Derives de benzimidazolidinone utilises comme agents muscariniques
WO2004089942A2 (fr) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Derives de benzimidazolidinone utilises en tant qu'agents muscariniques
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
MXPA04010172A (es) * 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
CA2488845A1 (fr) * 2002-06-17 2003-12-24 Merck & Co., Inc. Compositions ophtalmiques destinees a traiter l'hypertension oculaire
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
JPWO2004069828A1 (ja) * 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
AR054816A1 (es) * 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
EP1960389B1 (fr) 2005-09-30 2012-08-15 Glaxo Group Limited Composes exerçant une activite au niveau du recepteur m1 et leurs utilisations en medecine
US8288413B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
GB0605784D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
CN101616640B (zh) * 2006-12-26 2013-02-27 Qlt插入传输公司 用于抑制视觉缺陷的给药植入体
GB0706190D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31346A1 (es) * 2007-09-20 2009-04-30 Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
JP2010539217A (ja) * 2007-09-20 2010-12-16 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124883A1 (fr) * 2008-04-09 2009-10-15 H. Lundbeck A/S Nouveaux 1,3-dihydro-benzoimidazol-2-ones utilisés en tant qu’agonistes m1
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
JP6083818B2 (ja) 2011-11-18 2017-02-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニスト
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
WO2014122474A1 (fr) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Carboxylates de pipéridin-1-yle et d'azépin-1-yle à titre d'agonistes du récepteur muscarinique m4
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
WO2015138700A1 (fr) * 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Utilisation de zwitterions anticholinergiques sélectionnés
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
CA2981530A1 (fr) 2015-04-10 2016-10-13 Araxes Pharma Llc Composes quinazoline substitues et leurs procedes d'utilisation
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356349A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines mutantes kras g12c
WO2017058805A1 (fr) * 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
EP3356353A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (fr) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
WO2017100546A1 (fr) 2015-12-09 2017-06-15 Araxes Pharma Llc Procédés de préparation de dérivés de quinazoléine
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573971A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
EP3573964A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation
EP3573970A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
KR102633606B1 (ko) * 2017-03-23 2024-02-02 싱가포르 헬스 서비시즈 피티이 엘티디 활성 성분으로서 티오트로피움을 포함하는, 근시 예방, 근시 치료, 및/또는 근시 진행 예방을 위한 제제
WO2018174145A1 (fr) * 2017-03-23 2018-09-27 Singapore Health Services Pte Ltd Agent de prévention de la myopie, de traitement de la myopie, et/ou de prévention de la progression de la myopie comprenant de l'uméclidinium en tant que principe actif
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
EP3630746A1 (fr) 2017-05-25 2020-04-08 Araxes Pharma LLC Composés et leurs procédés d'utilisation pour le traitement du cancer
EP3630747A1 (fr) 2017-05-25 2020-04-08 Araxes Pharma LLC Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
CA1336490C (fr) * 1988-06-03 1995-08-01 Paul Michael Iuvone Traitement pharmacologique de la croissance anormale de l'oeil
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5322847A (en) * 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases

Also Published As

Publication number Publication date
JP2002515008A (ja) 2002-05-21
EP0786997A4 (fr) 1998-03-11
EP0786997A1 (fr) 1997-08-06
AU3967495A (en) 1996-05-23
WO1996013262A1 (fr) 1996-05-09
AU701127B2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
AU701127B2 (en) Muscarine antagonists
US5574044A (en) Muscarine antagonists
US5691323A (en) Muscarine antagonists
AU2006297089B2 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
NL1031532C2 (nl) Nieuwe verbindingen van aminosulfonylderivaten.
KR102190087B1 (ko) 트라이아졸로피라진
AU2011232347B2 (en) Compositions and methods for the treatment of degenerative diseases
US5756508A (en) Muscarine antagonists
CA2315117C (fr) Composes ether et thioether heterocycliques utilises dans la regulation de la transmission synaptique chimique
JPH08502481A (ja) 認識機能を向上させる複素環式エーテル化合物
AU2011291110B2 (en) Pyrimidine derivatives as FAK inhibitors
EP3322698A1 (fr) Composés d'indazole et d'azaindazole à titre d'inhibiteurs d'irak-4
PL192397B1 (pl) Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna
AU2006331850A1 (en) Substituted aniline derivatives useful as histamine H3 antagonists
AU2011282887A1 (en) Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
AU2008255328A1 (en) Pyridazinone derivatives
CA2810696A1 (fr) Compose de pyrazoloquinoline
WO1997016192A1 (fr) Antagoniste de la muscarine
AU2014334616A1 (en) Quinolinyl modulators of RORyt
JP2012532916A (ja) 特に睡眠障害及び薬物中毒の治療に適したスピロアミノ化合物
JP2008540500A (ja) ニューロキニン受容体拮抗物質としてのキノリン誘導体
KR20170054508A (ko) 신규 가용성 구아닐레이트 시클라제 활성화제 및 그의 용도
EP2313403A2 (fr) Dérivés de thiazolyl-piperidine
US20220306588A1 (en) Bezimidazole derivatives as adenosine receptor antagonists
BR112020001978A2 (pt) derivados de tiazolopiridina como antagonistas de receptor de adenosina

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead